Collaborators will carry out additional clinical research with the intent of using the technology along with traditional methods.

Laboratory Corporation of America (LabCorp) entered into an exclusive license agreement with Duke University Medical Center to commercialize the institute’s blood-based assay for early detection of lung cancer.

The Duke technology is based on a collection of serum proteins associated with the biology of lung cancer. Duke and LabCorp expect to conduct additional clinical studies with the biomarker technology prior to its commercial introduction.

“Our goal is to develop a cutting-edge technology that when combined with other modalities such as CT imaging can better differentiate true cancers from benign nodules,” says Edward Patz, M.D., James and Alice Chen professor of radiology.

Previous articleInvitrogen Set to Provide Comprehensive Noncoding RNA Portfolio
Next articleTranscriptional Complex Associated with Cancer and Normal Stem Cell Gene Expression